Treatment of Central Precocious Puberty by Subcutaneous Injections of Leuprorelin 3-Month Depot (11.25 mg)
The DOI matches its Crossref record.
Abstract
Depot GnRH agonists are widely used for the treatment of precocious puberty. Leuprorelin 3-month depot is currently used in adults but has not been evaluated in children. We evaluated the efficacy of this new formulation (11.25 mg every 3 months), for the suppression of gonadotropic activation and pubertal signs in children with central precocious puberty. We included 44 children (40 girls) with early-onset pubertal development in a 6-month open trial. The inclusion criteria were clinical pubertal development before the age of 8 (girls) or 10 (boys), advanced bone age, enlarged uterus (>36 mm), testosterone more than 1.7 nmol/liter (boys), and pubertal response of LH to GnRH (peak >5 IU/liter). The principal criterion for efficacy assessment, GnRH-stimulated LH peak less than 3 IU/liter, was met in 81 of 85 (95%) of the tests performed at months 3 and 6. The remaining four values were slightly above the threshold. The levels of sex steroids were also significantly reduced and clinical pubertal development was arrested. Plasma leuprorelin levels, measured every 30 d, were essentially stable after d 60. Local intolerance was noted after 10 of 86 injections (12%), and was mild in four cases, moderate in five cases, and severe in one. Among these 10 events, 4 consisted in local pain at injection's site. In conclusion, leuprorelin 3-month depot efficiently inhibits the gonadotropic axis in 95% of children with central precocious puberty studied for a 6-month period. This regimen allows the reduction of the number of yearly injections from 12 to 4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
Carel, J.-C., Eugster, E. A., Rogol, A., Ghizzoni, L., Palmert, M. R., & on behalf of the members of the ESPE-LWPES GnRH Analogs Consensus Conference Group (2009) · Pediatrics · doi:10.1542/peds.2008-1783 · Cited by 817
Self-citationCarel, J.-C., & Léger, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0800459 · Cited by 761
Self-citationCauses, diagnosis, and treatment of central precocious puberty
Latronico, A. C., Brito, V. N., & Carel, J.-C. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00380-0 · Cited by 518
Self-citationPrecocious puberty and statural growth
Carel, J.-C. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh012 · Cited by 319
Self-citationTreatment and Outcomes of Precocious Puberty: An Update
Fuqua, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1024 · Cited by 260
Metadata
- Authors
- Carel, J.-C., Lahlou, N., Jaramillo, O., Montauban, V., Teinturier, C., Colle, M., Lucas, C., T. F. L. T. G., & Chaussain, J. L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-09-01
- Volume
- 87
- Issue
- 9
- Pages
- 4111-4116
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2111793458
- Cited by
- 108
- References
- 0
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Central Precocious Puberty by Subcutaneous Injections of Leuprorelin 3-Month Depot (11.25 mg). https://app.cochat.ai/papers/10.1210/jc.2001-020243
- The paper
- Carel, J.-C., Lahlou, N., Jaramillo, O., Montauban, V., Teinturier, C., Colle, M., Lucas, C., T. F. L. T. G., & Chaussain, J. L. (2002). Treatment of Central Precocious Puberty by Subcutaneous Injections of Leuprorelin 3-Month Depot (11.25 mg). The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2001-020243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.